Corvus Pharmaceuticals Presents Promising Preclinical Data on Soquelitinib for Systemic Sclerosis Treatment

Corvus Pharmaceuticals presented preclinical data on soquelitinib at EULAR 2025, highlighting its potential to treat systemic sclerosis. The research suggests soquelitinib may prevent lung damage, inflammation, and pulmonary hypertension associated with the disease. The data was selected as a top 10 abstract by EMEUNET, underscoring its scientific significance. Corvus Pharmaceuticals is primarily focused on the Phase 3 trial of soquelitinib for peripheral T cell lymphoma, but is considering potential future applications for systemic sclerosis.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, presented preclinical data on its lead ITK inhibitor, soquelitinib, at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, held from June 11-14, 2025, in Barcelona. The research, presented by Gonçalo Boleto, M.D., MSc, a rheumatologist at Centro Académico de Medicina de Lisboa, Portugal, highlighted the potential of soquelitinib to treat systemic sclerosis [1].

The data, selected as a top 10 abstract by the Emerging EULAR Network (EMEUNET), suggests that soquelitinib may prevent lung damage, inflammation, and pulmonary hypertension associated with systemic sclerosis. The research builds on previous findings presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology.

While Corvus Pharmaceuticals is primarily focused on developing soquelitinib via its registration Phase 3 trial for peripheral T cell lymphoma and Phase 1 trial for atopic dermatitis, the company is considering potential future applications for systemic sclerosis. The company's president and CEO, Richard A. Miller, M.D., emphasized the strong interest in ITK inhibition as a new approach to treating immune-mediated fibrotic diseases [1].

Corvus Pharmaceuticals is pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The company's lead product candidate, soquelitinib, is an investigational, oral, small molecule drug that selectively inhibits ITK. The company's other clinical-stage candidates are being developed for a variety of cancer indications.

The presentation of the preclinical data at EULAR 2025 underscores the scientific significance of Corvus Pharmaceuticals' research. The company's forward-looking statements highlight the potential of soquelitinib and ITK inhibition in systemic sclerosis, but also acknowledge the risks and uncertainties associated with clinical trials and regulatory processes [1].

References:
[1] https://www.biospace.com/press-releases/corvus-pharmaceuticals-presents-soquelitinib-preclinical-data-highlighting-potential-of-itk-inhibition-to-treat-systemic-sclerosis-at-eular-2025-congress